R&D channel feed

Go­ing glob­al, Take­da opens up 165,000-square-foot R&D fa­cil­i­ty in San Diego

7 years ago

Ter­ry Rosen is look­ing to leave the thun­der­ing herd and blaze a new trail in PD-1 R&D

7 years ago
People

The BC­MA fren­zy: Track­ing the 37 drugs around the world rac­ing to over­take blue­bird bio and Cel­gene

7 years ago

Why did GSK kill two vac­cine R&D pro­grams? CEO Em­ma Walm­s­ley is glad you asked

7 years ago

Man­u­fac­tur­ing con­cerns spike Nabri­va’s plans to launch its first an­tibi­ot­ic — for now

7 years ago

In­cyte pulls away 'dam­aged good­s' baric­i­tinib to fo­cus on in­ter­nal pipeline

7 years ago

Suf­fer­ing a se­ries of set­backs, Eli Lil­ly's on­col­o­gy group qui­et­ly ex­e­cutes 2 of its top mid-stage drugs

7 years ago

As Eli Lil­ly suf­fers a sharp set­back on rev­enue pro­jec­tions, the on­col­o­gy group qui­et­ly ex­e­cutes 2 of its top mid-stage drugs

7 years ago

EU uni­ver­si­ties are mis­er­ably lax at re­port­ing clin­i­cal tri­al re­sults, analy­sis sug­gests

7 years ago

FDA tags Bay­er's prostate can­cer drug for pri­or­i­ty re­view as drug­mak­er gears up against ri­vals

7 years ago

Keytru­da PhI­II fail­ure in gas­tric can­cer blights Mer­ck­'s quest for front­line dom­i­nance

7 years ago
Pharma

Cel­e­brat­ing sus­tained sales growth, As­traZeneca qui­et­ly ex­e­cutes some ag­ing mid-stage drug projects

7 years ago

Gilead­'s selon­sert­ib fails PhI­II in less sick NASH pa­tients — to no one's sur­prise

7 years ago

An­oth­er one of Bris­tol-My­er­s' PD-1/CT­LA-4 com­bo stud­ies bites the dust

7 years ago

In­censed by Chi­na CRISPR scan­dal, US con­sor­tium am­pli­fy glob­al call to sus­pend hu­man em­bryo edit­ing

7 years ago
Pharma

What does the past gen­er­a­tion of fail­ure in Alzheimer’s R&D look like in one slide?

7 years ago

An 'oblig­a­tion to re­bound': Bio­gen backs fur­ther away from ad­u­canum­ab as R&D team hunts down late-stage M&A op­por­tu­ni­ties

7 years ago

Anx­ious to fill Hu­mi­ra-sized rev­enue hole ahead of US patent cliff, Ab­b­Vie hits the ground run­ning with FDA ap­proval for Skyrizi

7 years ago
Pharma

Te­va’s mi­graine drug can’t stop an­oth­er bad R&D headache as re­searchers scrap a failed PhI­II pro­gram for Ajovy

7 years ago
Pharma

GSK punts a failed car­dio drug to a biotech start­up — which has a new de­vel­op­ment strat­e­gy in mind

7 years ago
Startups

The biotech era in late-stage drug R&D and mar­ket­ing has ar­rived. And it looks like it’s here to stay

7 years ago

As safe­ty looms larg­er in CAR-T re­search, study high­lights how small tweaks can make it eas­i­er to use

7 years ago
Cell/Gene Tx

Pos­i­tive piv­otal Lil­ly da­ta set stage for Taltz ap­proval in non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis

7 years ago

As ri­vals wait in line, Mer­ck­'s Keytru­da scores ear­ly FDA nod for front­line pa­tients with the most com­mon form of kid­ney can­cer

7 years ago
Pharma
First page Previous page 249250251252253254255 Next page Last page
A service from the Financial Times